

Speeding up assay development with automated workflow for assessing plate bias of microtiter plate assays

Tomasz Witkos¹ and Hadley Myers²

UK JMP Users Group Meeting



 $^{^{\}rm 1}$ Bioassay, Biosafety and Impurities, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK

² Senior System Engineer, JMP UK & Ireland, SAS

Acknowledgements

Biopharmaceutical Development, AstraZeneca:

- Deepika Srivastava
- Barbara Hebeis





Presentation outline

- 1 Potency testing of biologics
- 2 Using microtiter plates in bioassays
- 3 Plate bias and uniformity
- 4 JMP demo



Putting Potency Assays into Drug R&D Perspective






Which molecule has biological activity?

Is the biological activity at a similar level between lots? (Lot-to-lot consistency)




Potency assays as part of a typical biopharmaceutical manufacturing process






Screening vs potency assays - measuring biological activity





Screening/Selection Bioassays:

Resolve log scale differences between different drugs



• Standard
□ Test
Standard fit
Test fit
□

log(dose)

https://www.quantics.co.uk/qubas-bioassay-software2/qubashelp/relative_potency_1.htm

CMC Potency Assays:

Resolve within 2 fold change between


different lots of the same drug



Common types of potency assays




Non cell-based target binding assays




Recombinant target coated on a microtiter plate

Cell-based target binding assays



Quantification of target binding


Cell-based reporter assays



Quantification of effect of target binding – activation/inhibition




Microtiter plates in potency assays




- Most common type: 96-well
- Less common: 384-well and 1536-well

- 1 assay run = one or multiple plates (depends on in-plate and plate-to-plate variability)
- On each plate dilution series of a reference standard and samples










Data and curve fitting in potency testing




- Response data is used to generate a dose-response model fit (non-linear – 4PL or based on data transformation, e.g., log10)
- Pairwise comparison of fits between the standard and sample with shared lower and upper asymptotes, and growth rate
- Inflection point (EC_{50} or IC_{50}) difference = % relative potency

Estimate

Parameter


Growth Rate


Group



Parameter


Potency assay development





- Accuracy
- Linearity
- Precision
- Range
- Specificity
- Stability indicating potential











Scale matters!

Cell Name colored by Data





Analysis by plate row

Plate Row









Plate Row


Patterns of variability can be non-random




Changes in average responses









Changes in variability









Case study – plate uniformity








- Many binding assays have similar step but they can differ + differences in liquid volumes, incubation times, buffers, reagent concentrations and plate types used
- Plate uniformity has to be conducted for every assay we develop
- Many potential sources of variability, including the operator



Old analysis workflow

Manual data import into Excel sheet







Manual data arrangement into dilution series/plate




EC₅₀/IC₅₀ calculation in a different software





Manual analysis in JMP





Manual data arrangement in Excel

		1		
JMP Table				
Plate	Row	IC50	Prep	Run
1	Α	44.94	1	1
1	В	50.45	1	1
1	С	59.97	1	1
1	D	52.21	1	1
1	Е	50.89	1	1
1	F	38.98	1	1
1	G	61.34	1	1
1	Н	52.21	1	1
2	Α	46.57	2	1




IC50

Manual inflection point import into Excel


-									
		Α	В	С	D	Е	F	G	Н
	Plate 1	44.94	50.45	59.97	52.21	50.89	38.98	61.34	52.21
	Plate 2	46.57	54.64	65.81	67.01	60.76	71.29	49.63	68.22
	Plate 3	45.48	68.02	85.78	32.41	62.38	46.06	36.64	52.52
	Plate 4	41.63	43.05	55.89	60.85	53.39	56.7	56.18	53.47
	Plate 5	38.88	48.76	68.42	49.46	64.56	64.93	53.07	44.93
	Plate 6	40.74	46.65	54.03	57.98	62.19	54.02	41.69	34.11




Improved analysis workflow



Curve bias analysis



Fully employing JMP interactiveness







Benefits of the new tool

- Removal of manual, error-prone copy-paste of data
- "One stop-shop" for plate bias and uniformity analysis with most statistically sound models already chosen for users
- Plate heat map generation options allow removal of obvious data outliers to focus on "true" variability analysis
- Interconnectivity of curve analysis with plate row/column variability analysis
- More in-depth analysis of uncertainty in calculation of $\mathrm{EC}_{50}/\mathrm{IC}_{50}$ possible

Aiding and speeding up development of robust potency assays



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com

